Dasiglucagon
Sponsors
Zealand Pharma, Massachusetts General Hospital, Steno Diabetes Center Copenhagen, Filip Krag Knop, Inreda Diabetic B.V.
Conditions
Congenital HyperinsulinismDiabetes Mellitus, Type 1Glucose Metabolism DisordersHyperinsulinemic HypoglycemiaHypoglycemiaPostprandial HypoglycemiaType 1 DiabetesType 1 Diabetes Mellitus
Phase 1
Evaluation of the Safety, Tolerability and Bioavailability of Dasiglucagon Following Subcutaneous (SC) Compared to IV Administration
CompletedNCT03735225
Start: 2018-11-07End: 2019-06-24Updated: 2021-03-23
Research Study in Japan to Compare Dasiglucagon With Glucagon in Treating Very Low Levels of Blood Sugar in Asian Adults With Type 1 Diabetes and Testing of Dasiglucagon for the Same Condition in Japanese Adolescents
CompletedNCT06588504
Start: 2024-09-10End: 2025-07-20Updated: 2025-12-05
Phase 2
The Bihormonal iLet Bionic Pancreas Feasibility Study
CompletedNCT03840278
Start: 2019-05-15End: 2019-07-03Updated: 2019-12-16
Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism
CompletedNCT04172441
Start: 2020-06-19End: 2022-03-07Updated: 2025-03-14
Low-dose Dasiglucagon for Prevention of Insulin-Induced Hypoglycemia in People With Type 1 Diabetes
CompletedNCT04449692
Start: 2020-07-02End: 2021-01-04Updated: 2021-02-09
Pen-Administered Low-Dose Dasiglucagon for Prevention and Treatment of Hypoglycemia in People With Type 1 Diabetes
CompletedNCT04764968
Start: 2021-04-27End: 2022-01-28Updated: 2022-09-07
Efficacy and Safety of Dasiglucagon for Treatment of Post-bariatric Hypoglycemia in Roux-en-Y Gastric Bypass (RYGB) Operated Adults
WithdrawnNCT04824872
Start: 2023-02-28End: 2023-02-28Updated: 2023-02-21
Treatment of Post-bariatric Hypoglycaemia
CompletedNCT04836273
Start: 2021-08-20End: 2022-12-15Updated: 2023-02-02
A Stable Glucagon Analog Administered by a Bihormonal Closed Loop System
WithdrawnNCT05454709
Start: 2023-12-29End: 2023-12-29Updated: 2024-01-03
Phase 3
A Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen in Patients With Type 1 Diabetes Mellitus
CompletedNCT03216226
Start: 2017-06-28End: 2018-02-13Updated: 2021-05-04
A Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Type 1 Diabetes Subjects
CompletedNCT03378635
Start: 2017-12-07End: 2018-05-25Updated: 2021-06-10
Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in T1DM Children
CompletedNCT03667053
Start: 2018-09-28End: 2019-06-28Updated: 2021-06-30
Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Subjects With T1DM
CompletedNCT03688711
Start: 2018-11-01End: 2019-03-11Updated: 2021-05-19
A Two-Period Open-label Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism
CompletedNCT03777176
Start: 2019-02-07End: 2020-10-05Updated: 2023-12-13
A Trial to Compare the Efficacy and Safety of 2 Different Batches of Subcutaneous Dasiglucagon in Patients With T1DM
CompletedNCT03895697
Start: 2019-03-26End: 2019-07-30Updated: 2023-02-21
Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism
Active, not recruitingNCT03941236
Start: 2019-05-02End: 2026-12-31Updated: 2026-01-20
A Study to Inv. Safety, Efficacy & PD of Dasiglucagon as Hypoglycemia Rescue Therapy in Children <6 Years With T1D
CompletedNCT05378672
Start: 2023-05-09End: 2024-12-03Updated: 2025-07-20